Skip to content
Confronting the Crisis: New Tools to Meet the Challenge of Multidrug-Resistant Bacteria
Pre-Activity Survey
Pre-Test
1.
All of the following were identified by the World Health Organization as critical priority pathogens except:
Methicillin-resistant
S. aureus
Carbapenem-resistant
P. aeruginosa
Carbapenem-resistant
A. baumannii
Carbapenem-resistant, ESBL-producing Enterobacteriaceae
2.
Newer beta-lactam/beta-lactamase inhibitor agents (i.e., ceftolozane-tazobactam, ceftazidime-avibactam) exhibit activity against all of the following resistant organisms except:
ESBL-producing
K. pneumoniae
Fluoroquinolone-resistant
E. coli
Metallo-beta-lactamase-producing
K. pneumoniae
Multidrug-resistant
P. aeruginosa
3.
TEM-1, TEM-2, and SHV-1 all belong to the beta-lactamase ambler class:
A
B
C
D
4.
Which of the following is the most appropriate initial antimicrobial for a 72-year-old man with a complicated UTI caused by an ESBL-producing
K. pneumoniae
?
Moxifloxacin
Ceftazidime
Meropenem
Linezolid
5.
Which of the following agents in development exhibits the greatest in vitro activity against
Acinetobacter baumannii?
Imipenem-relebactam
Cefiderocol
Meropenem-vaborbactam
Plazomicin
6.
Risk factors for infection caused by a multidrug-resistant Gram-negative organism include all of the following except:
High prevalence of institutional MDR bacteria
Prophylactic use of antimicrobials
Cystic fibrosis
No previous history of MDR infection